Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rationale for a new triphasic oral contraceptive.

S A Pasquale1

  • 1Department of Obstetrics and Gynecology, UMDNJ--Robert Wood Johnson Medical School, New Brunswick.

International Journal of Fertility
|January 1, 1986
PubMed
Summary

New oral contraceptive (OC) formulations with reduced hormone levels offer high effectiveness. This triphasic norethindrone and ethinyl estradiol regimen shows fewer side effects than other low-dose options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.

American journal of obstetrics and gynecology·1998
Same author

Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women.

Fertility and sterility·1997
Same author

Lack of interaction between magnetic resonance imaging and the copper-T380A IUD.

Contraception·1997
Same author

Irregular bleeding, body mass index and coital frequency in Norplant contraceptive users.

Contraception·1994
Same author

Future directions in contraception.

Current opinion in obstetrics & gynecology·1992
Same author

Noncontraceptive health benefits and risks of steroidal contraception.

International journal of fertility·1989

Area of Science:

  • Reproductive Health
  • Endocrinology
  • Pharmacology

Background:

  • Traditional oral contraceptives (OCs) containing estrogen and progestogen have been linked to adverse effects.
  • A need exists for OC formulations with reduced hormonal content to minimize side effects.

Purpose of the Study:

  • To evaluate a novel triphasic oral contraceptive regimen with decreased progestogen and estrogen doses.
  • To assess the efficacy and side effect profile of this new OC formulation.

Main Methods:

  • A triphasic regimen was studied: 0.5 mg norethindrone + 35 mcg ethinyl estradiol (days 1-7), 0.75 mg norethindrone + 35 mcg ethinyl estradiol (days 8-14), and 1 mg norethindrone + 35 mcg ethinyl estradiol (days 15-21).
  • Effectiveness and incidence of common side effects were monitored across menstrual cycles.

Main Results:

  • The triphasic OC formulation demonstrated high contraceptive effectiveness.
  • This regimen was associated with a reduced incidence of side effects compared to other low-dose OCs.

Conclusions:

  • The studied triphasic oral contraceptive regimen is a highly effective option for preventing pregnancy.
  • This formulation offers a favorable side effect profile, potentially improving user compliance and satisfaction.

Related Experiment Videos